EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma

Purpose: EphA2 (epithelial cell kinase) is a transmembrane receptor tyrosine kinase that has been implicated in oncogenesis. There are no published data regarding the role of EphA2 in ovarian carcinoma, which is the focus of the present study. Experimental Design: Nontransformed (HIO-180) and ovaria...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2004-08, Vol.10 (15), p.5145-5150
Main Authors: THAKER, Premal H, DEAVERS, Michael, CELESTINO, Joseph, THORNTON, Angela, FLETCHER, Mavis S, LANDEN, Charles N, KINCH, Michael S, KIENER, Peter A, SOOD, Anil K
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Blotting, Western
Cell Line, Tumor
Female
Humans
Immunohistochemistry
Immunoprecipitation
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness
Ovarian Neoplasms - metabolism
Pharmacology. Drug treatments
Proportional Hazards Models
Receptor, EphA2 - biosynthesis
Time Factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: EphA2 (epithelial cell kinase) is a transmembrane receptor tyrosine kinase that has been implicated in oncogenesis. There are no published data regarding the role of EphA2 in ovarian carcinoma, which is the focus of the present study. Experimental Design: Nontransformed (HIO-180) and ovarian cancer (EG, 222, SKOV3, and A2780-PAR) cell lines were evaluated for EphA2 by Western blot analysis. Five benign ovarian masses, 10 ovarian tumors of low malignant potential, and 79 invasive ovarian carcinomas were also evaluated for EphA2 expression by immunohistochemistry. All samples were scored in a blinded fashion. Univariate and multivariate analyses were used to determine significant associations between EphA2 expression and clinicopathological variables. Results: By Western blot analysis, EG, 222, and SKOV3 cell lines overexpressed EphA2, whereas A2780-PAR and HIO-180 had low to absent EphA2 expression. All of the benign tumors had low or absent EphA2 expression. Among the invasive ovarian carcinomas examined (mean age of patients was 59.2 years), 60 (75.9%) tumors overexpressed EphA2 and the other 19 tumors had negative or minimal EphA2 expression. There was no association of EphA2 overexpression with ascites, likelihood of nodal positivity, pathological subtype, and optimum surgical cytoreduction (residual tumor
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-03-0589